A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VTX3232 Alone or in Combination With Semaglutide in Participants With Obesity
Latest Information Update: 07 Feb 2025
Price :
$35 *
At a glance
- Drugs VTX 3232 (Primary) ; Semaglutide
- Indications Obesity
- Focus Adverse reactions
- Sponsors Zomagen Biosciences
- 20 Jan 2025 New trial record
- 14 Jan 2025 According to a Ventyx Biosciences media release, topline results from this trial expected in the second half of 2025.